Inactive Instrument

ReNeuron Group Plc Stock price London S.E.

Equities

Biotechnology & Medical Research

Sales 2022 403K 509K Sales 2023 530K 670K Capitalization 5.17M 6.54M
Net income 2022 -9M -11.37M Net income 2023 -5M -6.32M EV / Sales 2022 8.48 x
Net cash position 2022 13.99M 17.67M Net cash position 2023 6.73M 8.51M EV / Sales 2023 -2.94 x
P/E ratio 2022
-1.79 x
P/E ratio 2023
-0.96 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 79.3%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Director of Finance/CFO 58 14-09-30
Chief Operating Officer - 16-12-31
Chief Tech/Sci/R&D Officer - 22-03-02
Members of the board TitleAgeSince
Director/Board Member 61 22-03-21
Chairman 71 21-06-30
Director/Board Member 61 21-07-13
More insiders
ReNeuron Group plc is a United Kingdom-based Stem Cell and Exosome Technologies company that utilizes its stem cell technologies to develop treatments for disease with unmet needs. The Company has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities. The Company's CustomEX platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. The Company offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
More about the company
  1. Stock
  2. Equities
  3. Stock ReNeuron Group plc
  4. Stock ReNeuron Group Plc - London S.E.